Compare Indonesia Energy Corporation Limited (INDO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs State Street SPDR S&P Biotech ETF — how do they compare? Indonesia Energy Corporation Limited trades at $2.92 (market cap $45.55M), while State Street SPDR S&P Biotech ETF trades at $159.13. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| INDO | XBI | |
|---|---|---|
Market Cap | $45.55M | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $6.74 | $164.28 |
52-Week Low | $2.49 | $86.92 |
Enterprise Value | $40.92M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.97, up 1.71% today, with a bullish technical signal supported by moving averages. The company reported a net loss of $5 million on $2 million revenue in 2025, resulting in negative profit margins. Recent news highlights operational progress with the commencement of drilling at the K-29 well in Indonesia. Analyst consensus is unanimously bullish with three buy ratings.
The outlook hinges on successful well development driving future revenue growth, but high valuation multiples and persistent losses pose significant risks. Investors face volatility from execution challenges in oil and gas exploration, though positive analyst sentiment suggests potential upside if operational milestones are met.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
